ArticleFrontiers in medicine2026
PRAISE-H study exploring real-world challenges faced by reproductive-age patients with rheumatoid arthritis in Japan.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We explored the design and preliminary findings of the Pregnancy and Rheumatoid Arthritis Registry (PRAISE-H), a Japan-wide prospective registry of reproductive-age patients with rheumatoid arthritis (RA) that captures challenges in daily life and complements large database research. PRAISE-H is a nationwide multicentre prospective observational study in which physician assessments and patient-reported outcomes are collected biannually via REDCap over 5 years, with dedicated follow-up during pregnancy and up to 12 months postpartum. As of November 2024, 100 patients (90 women and 10 men) had been registered, and 77 patients (70 women and seven men) were under follow-up. Preliminary analyses showed that 62% of women expressed current or future pregnancy intention. In addition, substantial financial toxicity was observed, particularly among patients receiving biologic disease-modifying antirheumatic drugs (bDMARDs). By emphasizing patients' experiences in everyday environments, PRAISE-H provides insights beyond the scope of conventional database studies. These findings may inform clinical guidelines and health policy initiatives aimed at improving the management of RA in women of childbearing age. Although bDMARDs are increasingly considered viable treatment options during pregnancy, their associated financial consequences warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.